

**Bharat Biotech wins Orissa Government's First PPP "Biotech Pharma IT Park"  
Project.**

The Orissa State Government is developing a state of the art Biotech Pharma IT Park over an area about 64.86 acres at Mouza-Andharua, Bhubaneswar on Public-Private-Partnership (PPP) mode. The Park, the first of its kind in Orissa envisages promotion of Biotech, Pharmaceuticals and IT industries in the State. The State Govt has recently selected M/s Bharat Biotech International Ltd as the 'Developer' for this prestigious project.

The State Government of Orissa has allocated 54.86 acres of land to Bharat Biotech towards the development of an integrated industrial park to attract and promote pharmaceutical, biotechnology and information technology industries in Bhubaneswar in the Private Public Partnership mode. The development of this integrated park would help kick start investments in the areas of biotechnology and pharmaceuticals in Orissa. The land has been allocated in the form of a long term lease to Bharat Biotech with commitments of time bound development of infrastructure and facilities. Bharat Biotech led by Dr. Krishna Ella Chairman and Managing Director proposes to focus on rapid development of this park by developing core infrastructure and technology to enable establishment of new companies whereby new local Entrepreneurs in the Biotechnology field will be created. Bharat Biotech will also strive to bring in Biotechnology, Pharmaceuticals and IT Industries in the State of Orissa. They will also help in the creation and up gradation of skills in human resources in the areas of biotechnology, pharmaceutical sciences and information technology in the State.

Bharat Biotech, the selected Developer, has significant prior experience in the development and successful commercialization of technology parks in India. Bharat Biotech has successfully developed an integrated food biotech park in Bangalore. Dr. Krishna Ella was also instrumental in the establishment and development of the Genome Valley BioPharmaceutical cluster located in the outskirts of Hyderabad.

Bharat Biotech will form a Special Purpose Vehicle (SPV) to develop the BT-Pharma-IT Park at Andharua. The SPV will execute the Lease cum Development Agreement of the Bharat Biotech with Orissa Industrial Infrastructure Development Corporation (IDCO). The estimated cost for development of the project by M/s Bharat Biotech International Limited, Hyderabad is about Rs.100 crores. This project will be completed in 8 years by the Developer. The State Govt of Orissa and IDCO have agreed to provide all external infrastructure facilities, such as road connectivity, water supply, power supply with 33 KVA sub-station etc to facilitate rapid development of internal infrastructure.

Within this Park over another 10 acres a Biotechnology Incubation Centre will be developed for use by researchers, entrepreneurs and students. The Department of Biotechnology, Govt of India, has assured funding for the equipment/instrumentation of this center of excellence within the park and Bharat Biotech will provide the necessary building infrastructure.

## **About Bharat Biotech**

Bharat Biotech International Limited, Hyderabad, India, is a multidimensional biotechnology company specializing in product-oriented research, development and manufacturing of vaccines and biotherapeutics. Bharat Biotech was established in the year 1996, is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research. Bharat Biotech is the first bio-pharma facilities in India to be audited and approved by Korean Food & Drugs Administration (KFDA). Bharat Biotech sprawls over a picturesque campus at Genome Valley, Hyderabad, built with an investment of over USD 100 million, the facility's manufacturing, control procedures and protocols, conform to the stringent standards laid down by internationally recognized institutions such as USFDA, UKMCA and WHO. Bharat has set new benchmarks in Innovation and Quality that epitomizes the tremendous progress of Indian biotechnology in the global arena. Bharat Biotech is the first to manufacture, INDIKINASE™, a recombinant Streptokinase and BIOGIT™, a yeast based probiotic yeast product in India. Bharat Biotech has commercialized India's first recombinant Epidermal Growth Factor, REGEN-D™ to combat diabetic foot ulcers, burns. Bharat Biotech has a strong pipeline of vaccines to combat Malaria, Rotavirus and Japanese Encephalitis infections.

For further details please contact:

B. Balaji Rao  
Head HR&Admin & Corp MIS  
Bharat Biotech International Ltd.  
[raobb@bharatbiotech.com](mailto:raobb@bharatbiotech.com)